Colorectal Cancer

The European Commission has approved encorafenib plus cetuximab and FOLFOX as the first BRAF-targeted regimen authorized in the EU for first-line BRAF V600E–mutant metastatic colorectal cancer.

A nurse-integrated mobile exercise app showed high usability, 80% exercise adherence, and significant fatigue improvements in a pilot study of adolescents with cancer.

Cost-utility analysis of the CHALLENGE trial showed structured exercise following adjuvant chemotherapy for colon cancer is cost-saving and improves QALYs.

FOLFIRI is viable as a chemotherapy backbone with the BREAKWATER regimen as a treatment for patients with frontline BRAF V600E-mutant metastatic colorectal cancer.

Data from the phase 3 CIRCULATE trial may justify ctDNA-guided treatment escalation strategies in pMMR stage II colon cancer.

A remote mobile health intervention tripled the odds of CRC screening completion in at-risk childhood cancer survivors in the randomized ASPIRES trial.

Adjuvant aspirin did not improve disease-free survival vs placebo in patients with stage III colorectal cancer who received standard adjuvant chemotherapy.

Serial ctDNA assessment after 3 months of adjuvant chemotherapy stratified recurrence risk and identified which patients with resected CRC benefit from extended treatment.

The European Medicine Agency’s CHMP has adopted a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in this treatment-naïve mCRC population.

Updated interim data from a phase 1/2 study of the DR5 agonist ozekibart plus FOLFIRI demonstrated a 20% ORR and 87% DCR in late-line colorectal cancer.

The incidence rates of breast cancer and colorectal cancer have been on the rise in patients under 50 years for the past several years.

Marc Lehrer Greenwald, MD, spoke with CancerNetwork® about how North Shore University Hospital treats young patients with colorectal cancer.

Marwan G. Fakih, MD, discussed many of the factors he considers when deciding on a treatment for a patient with metastatic colorectal cancer.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

Results from the BREAKWATER trial led to the traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy in BRAF-mutated CRC.

Phase 2 CRDF-004 findings show that adding onvansertib to FOLFIRI and bevacizumab improves PFS in first-line RAS-mutated metastatic colorectal cancer.

Encorafenib, cetuximab, and FOLFIRI improved PFS vs in treatment-naive BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER trial.

Prior phase 1 data support the fast track designation for pelareorep as a treatment for those with KRAS-mutated microsatellite stable colorectal cancer.

Treatment with zanzalintinib plus atezolizumab led to improvements in OS and PFS vs regorafenib alone in patients with metastatic colorectal cancer.

According to investigators of the phase 3 SCOT trial, most patients with colon and rectal cancer should be receiving only 3 months of adjuvant treatment.

People who consumed 14 or more drinks per week experienced a higher risk of colorectal cancer compared with those who consumed one or fewer drinks.

Data from the phase 3 BREAKWATER trial demonstrated that encorafenib plus cetuximab and chemotherapy yields clinical benefit for this patient population.

The Taiwan FDA has approved nivolumab/ipilimumab for patients with MSI-H/dMMR metastatic colorectal cancer based on data from CheckMate 8HW.

Circulating tumor DNA may particularly help adjuvant treatment decision-making in stage II colon cancer, according to Nicholas Hornstein, MD, PhD.

No serious adverse effects were observed with CBM588 in patients at risk of colorectal adenoma recurrence.